ERBB2 and neoplasm: Genomic analysis of co-existing tumor lineages provides a unique window into the evolutionary dynamics of tumor drug resistance, and can help identify high- confidence resistance mechanisms, as we did here for ERBB2 activation and like prior work has done for various targeted therapies5,42.